SMMT
Another oncology cameo
Summit Therapeutics brought ivonescimab back into the spotlight at ASCO 2026, this time with global phase II data in first-line metastatic colorectal cancer. The headline is simple: the data came off as encouraging, which is exactly the kind of phrase biotech investors love to hear and rivals hate to see.
Why this matters to your portfolio
For Summit, this isn’t just a science fair ribbon. Ivonescimab is the company’s big swing, and every new dataset helps answer the same question: is this drug a one-trick wonder or a platform-level story? Positive colorectal cancer data broadens the narrative beyond any single indication and keeps the market’s attention on the asset.
The biotech version of “show your work”
At conferences like ASCO, the details matter more than the applause. Investors will be parsing the readout for clues on efficacy, safety, and whether the drug can keep stacking credible data across tumor types. If the market sees this as another de-risking step, that can support the stock. If the readout feels incremental, the excitement may fade faster than a conference tote bag.
Big picture: in biotech, momentum is built one poster session at a time — and Summit just added another slide to the deck.